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The enzymatic stability of synthetic methionine-enkephalin peptide analogues containing an
unnatural amino acid of the adamantane-type 3-5 was examined in human serum, at 37 °C, and
compared with the results of the degradation of the parent endogenous pentapeptide 1 and
the tripeptide, Tyr-Gly-Gly (2). Methionine-enkephalin (Tyr-Gly-Gly-Phe-Met, 1) and tripep-
tide 2 are rapidly degraded in 80 % human serum with half-lives of 12.2 and 23.0 minutes, re-
spectively, preferably by aminopeptidase cleavage of the N-terminal Tyr-Gly peptide bond. In-
corporation of the rigid and sterically hindered 1-adamantylglycine moiety into the peptide
sequence resulted in increased stability of compound 3, while compounds 4a and 5a were not
at all susceptible to the enzymes present in human serum. Strong binding of peptides 3-5 to hu-
man serum proteins was demonstrated.
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INTRODUCTION
Opioid peptides act as cell growth factors, in addition to
regulating neurotransmission/neuromodulation in the
nervous system. The native opioid growth factor (OGF),
methionine-enkephalin (Tyr-Gly-Gly-Phe-Met, 1), plays
a role in cell proliferation and tissue organization during
development, cellular renewal, wound healing, and an-
giogenesis, but also in cancer.1,2
To obtain more selective opioid peptides with im-
proved or novel activity profiles toward malignant dis-
eases, modifications using lipophilic moieties may be of
particular benefit to passive or active cellular absorption
by membrane penetration or attachment. The suscepti-
bility of the modified peptides to enzymatic degradation
may also decrease. Recently, we designed and synthesiz-
ed new analogues of methionine-enkephalin (1) by sub-
stituting either Gly2 or Gly2-Gly3 in 1 and/or in its shorter
N-terminal fragments by unnatural adamantane-derived
amino acids.3 Exclusively, the peptide analogues con-
taining Caa-dialkylated glycine or Ca-alkylated glycine
residues showed in vitro antitumor activity in the cell
lines HEp-2, HBL, SW-620 and Caco-2. In particular,
the pentapeptide Tyr-(R,S)-Aaa-Gly-Phe-Met (3) [Aaa =
(R,S)-(1-adamantyl)glycine] (Figure 1) showed the most
potent tumoricidal activity by inducing apoptosis in the
cell lines HEp-2 and SW-620. The obtained data sug-
gested synergism of [(S)- and [(R)-Aaa]-3 when investi-
gated together as a racemate. Hence, racemic 3 appears
to represents formulation of choice for future screening
of this molecule for cytotoxic properties. In addition, the
diastereomeric tripeptides Tyr-(S)-Aaa-Gly (4a) and Tyr-
(R)-Aaa-Gly (4b) showed similar, cell-selective, cytotoxic
effects on tumor cell lines irrespective of Aaa chirality.3
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In this paper we compare the metabolic stability of
pentapeptide 3, of the tripeptides 4 and of the dipeptides
Tyr-Aaa (5) in diluted human serum with serum stability
of methionine-enkephalin (1) and its shorter N-terminal
tripeptide fragment, Tyr-Gly-Gly (2).
EXPERIMENTAL
Methionine-enkephalin (1) and Tyr-Gly-Gly (2) were pur-
chased from Bachem. Human serum and p-nitro-L-phenylala-
nine were obtained from Sigma-Aldrich. o-Hydroxyphenyl-
acetic acid was obtained from Fluka. Literature procedures
were used for the synthesis of Tyr-(R,S)-Aaa-Gly-Phe-Met
(3) [Aaa = (R,S)-(1-adamantyl)glycine], Tyr-(S)-Aaa-Gly (4a),
Tyr-(R)-Aaa-Gly (4b), Tyr-(S)-Aaa (5a) and Tyr-(R)-Aaa (5b).3
Stability of Peptides 1-3, 4a and 5a in Human
Serum
For serum stability studies, an aliquot (8 × 10–4 mol dm–3) of
the respective peptide (1-3, 4a, 5a), supplemented with the
internal standards, o-hydroxyphenylacetic acid (40 mg/mL)
and p-nitro-L-phenylalanine (20 mg/mL), was dissolved in
80 % human serum (5 mL, diluted with water), and kept at
37 °C in a teflon lined screw-cap test tube. Three samples
(0.1 mL) were removed at appropriate time intervals and
deproteinized by addition of 48 % aqueous TFA (0.02 mL).
The samples were briefly vortexed and frozen. The thawed
samples were centrifuged for 10 min (15000 g) and the con-
centration of the starting compounds and metabolites in the
supernatants was monitored by RP HPLC on an analytical
column (250 × 4 mm I.D., 5 mm) at a flow rate of 0.5
mL/min, with 40 % MeOH/0.1 % TFA for compound 1,
20.25 % MeOH/0.1 % TFA for compound 2 and tyrosine,
and 50.5 % MeOH/0.1 % TFA for compounds 3, 4a and 5a,
using a HP 1090 system equipped with a diode-array detec-
tor. UV absorbance was monitored at 280 and 215 nm.
Binding of Peptides 1-3, 4a and 5a to Human
Serum Proteins
The affinity of serum proteins for peptides 1-3, 4a and 5a
was analyzed by dissolving peptide compound (8 × 10–4
mol dm–3), and the internal standards, o-hydroxyphenylacetic
acid (40 mg/mL) and p-nitro-L-phenylalanine (20 mg/mL),
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Figure 1. Structure of peptides 1-5.
in water, in 80 % human serum or in 0.0008 mol dm–3
phosphate buffer/0.1 mol dm–3 NaCl (pH = 7.4) containing
human serum albumin (HSA) (50 mg/mL). The samples
dissolved in human serum or in HSA were deproteinized as
described above and analyzed by RP HPLC in solvent sys-
tems indicated in the previous section. The concentration of
the unbound peptide was determined by electronic integra-
tion of the peak areas and calculation of the analyte/internal
standard peak-ratios.
RESULTS AND DISCUSSION
It is known that enkephalins and their shorter fragments
are rapidly degraded in human blood plasma, the pre-
dominant ( 80 %) route for the degradation being hy-
drolysis of the N-terminal Tyr1-Gly2 bond by aminopep-
tidases.4,5
Proteolytic degradations of peptides 1-5 was exam-
ined at 37 °C in 80 % human serum. In agreement with
published results, we found rapid disappearance of pep-
tides 1 and 2 in human serum. Specifically, the half-lives
for methionine-enkephalin (1) and Tyr-Gly-Gly (2) were
12.2 min and 23.0 min, respectively. While methionine-
enkephalin (1) itself was rapidly degraded, the pentapep-
tide analogue Tyr-(R,S)-Aaa-Gly-Phe-Met (3) was very
slowly converted to tripeptides 4a and 4b (Figures 2B,
2C) indicating that only dipeptidyl carboxypeptidase(s)
are involved in the hydrolysis of peptide 3. After 4 days
of incubation in human serum, the relative amounts of
tripeptides 4a and 4b reached only 19 % and 16 %, re-
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Figure 2. RP HPLC elution profile of (A) peptides 3-5; (B) deproteinized solution of compound 3 in 80 % human serum at t = 0; (C)
deproteinized solution of compound 3 in 80 % human serum after 4 days of incubation at 37 °C. The mobile phase was 50.5 %
MeOH/0.1 % TFA at a flow of 0.5 mL/min. Each compound was dissolved individually in phosphate buffer (pH = 7.4) (panel A) or in hu-
man serum (panels B and C) at concentration of 8 × 10–4 mol dm–3. The injection volume was 20 mL. The absorbance was recorded at
280 nm. IS = internal standard (o-hydroxyphenylacetic acid). Observe the decreased absorbance of peptide 3 in panels B and C due to
binding to serum proteins (see Experimental and Figure 3 for details).
spectively. The structurally related smaller peptides
Tyr-(S)-Aaa-Gly (4a) and Tyr-(S)-Aaa (5a), under iden-
tical experimental conditions, showed no sign of degra-
dation over the time span investigated (14 days). The
stability of the corresponding diastereomers 4b and 5b
could not be determined because of their water-insolu-
bility.
Binding to serum proteins profoundly affects the
suitability of bioactive peptides for biomedical applica-
tion. Based on the observation that the absorbance of
Tyr-(R,S)-Aaa-Gly-Phe-Met (3) at 280 nm decreased af-
ter dissolution in human serum (Figures 2B, 2C), the
absorbances of peptides 1-3, 4a and 5a were compared
following dissolution in water, 80 % human serum or in
a solution of human serum albumin (HSA). As illus-
trated in Figure 3, after dissolution in human serum, and
deproteinization, the absorbance of compounds 3, 4a
and 5a decreased by 45 %, 9 % and 31 %, respectively,
while the absorbance of methionine-enkephalin (1) and
Tyr-Gly-Gly (2) remained unchanged. Almost identical
results were obtained when the respective peptides were
dissolved in a solution of HSA; this suggests that the ob-
served decrease in absorbance is likely due to binding to
the latter (major) serum protein.
In conclusion, the enzymatic stability and serum
protein affinity of methionine-enkephalin and its ana-
logues 3-5 were compared. The incorporation of the
rigid and sterically hindered 1-adamantylglycine moiety
into the peptide sequence resulted in increased stability
of compound 3, while compounds 4a and 5a were to-
tally insusceptible to the enzymes present in human se-
rum. Strong binding of peptides 3-5 to human serum
proteins was demonstrated.
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In Vitro enzimska stabilnost analoga metionin-enkefalina s ugra|enom neprirodnom
aminokiselinom adamantanske strukture
Maja Ro{~i}, Vanja Sablji}, Kata Mlinari}-Majerski i [tefica Horvat
Ispitana je enzimska stabilnost sintetskih peptidnih analoga metionin-enkefalina, koji sadr`e neprirodnu
aminokiselinu adamantanske strukture 3-5, u humanom serumu pri 37 °C, te uspore|ena s rezultatima enzimske
razgradnje ishodnih peptida, endogenog pentapeptida 1 i tripeptida, Tyr-Gly-Gly (2). Ustanovljena je vrlo brza
hidroliza metionin-enkefalina (1) (t1/2 = 12,2 min) i tripeptida 2 (t1/2 = 23,0 min) u humanom serumu,
mehanizmom koji se zbiva ponajprije djelovanjem aminopeptidaze na Tyr-Gly peptidnu vezu. Ugradnja rigid-
nog i voluminoznog 1-adamantilglicinskog ostatka u peptidnu strukturu uzrokuje pove}anu stabilnost spoja 3 i
potpunu stabilnost spojeva 4a i 5a prema enzimima prisutnim u humanom serumu. Uo~ena je sklonost vezanja
peptida 3-5 na proteine humanog seruma.
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Figure 3. Comparison of the binding affinities of peptides 1-3,
4a and 5a for serum proteins. The relative concentrations of un-
bound peptides were determined by RP HPLC.
